LDN 193189 GMP

Product Description

LDN 193189 synthesized to cGMP guidelines. Suitable for use as an ancillary reagent in the further manufacturing of cell therapies.

Research use only LDN 193189 also available.

For more information about how LDN 193189 dihydrochloride may be used, see our protocols: Generation of β cells from hPSCs, Generating Midbrain Dopaminergic Neurons from hPSCs, Accelerated Induction of Cortical Neurons from hiPSCs.

Licensing Information

Sold for research purposes only under exclusive agreement from The Brigham and Women's Hospital Inc. US patents 8,507,501 and 9,045,484. A license may be required for use in stem cell-based therapies. Please contact Technical Support for further details: techsupport@bio-techne.com.

Current Good Manufacturing Practice (cGMP) is a harmonized set of guidelines that when implemented will ensure safe, reliable, consistent and quality-assured products. The Tocris range of cGMP small molecules is manufactured following relevant sections of ICH Q7 guidelines. Our highly skilled team has full control over the cGMP process, meaning we can ensure: a quality-assured manufacturing system, batch-to-batch consistency, consistent supply, traceability from starting material to final product, and animal-free production. Find out more about the Tocris range of cGMP compounds.

Calculators